Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01877395 | Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen | PHASE2 | COMPLETED | 342 | — | — | Jun 1, 2013 | Sep 1, 2014 | Dec 3, 2014 | 5 | United States |
Rabies virus neutralizing antibody titer will be determined by the rapid fluorescent focus inhibition test (RFFIT)
| Arm | Type | Description |
|---|---|---|
| Purified Vero Rabies Vaccine Group | EXPERIMENTAL | Participants will receive the Purified Vero Rabies Vaccine (VRVg) |
| Imovax® Rabies Vaccine Group | EXPERIMENTAL | Participants will receive the Imovax® Rabies vaccine |
| Name | Type | Description |
|---|---|---|
| Purified Vero Rabies Vaccine (VRVg) | BIOLOGICAL | 0.5 mL, Intramuscular |
| Imovax® Rabies: inactivated rabies vaccine | BIOLOGICAL | 1.0 mL, Intramuscular |
Inclusion Criteria: * Aged 18 to \< 65 years on the day of inclusion * Informed consent form has been signed and dated - Able to attend all scheduled visits and comply with all trial procedures. Exclusion Criteria: * Subject is pregnant, or lactating, or of childbearing potential (to be considere...